Pfizer Inc. (NYSE:PFE) Shares Sold by DAVENPORT & Co LLC

DAVENPORT & Co LLC trimmed its holdings in Pfizer Inc. (NYSE:PFEFree Report) by 11.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 345,139 shares of the biopharmaceutical company’s stock after selling 44,593 shares during the period. DAVENPORT & Co LLC’s holdings in Pfizer were worth $9,937,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in PFE. Moneta Group Investment Advisors LLC boosted its holdings in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after purchasing an additional 160,963,976 shares during the last quarter. Norges Bank purchased a new stake in Pfizer in the fourth quarter valued at $3,150,472,000. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley boosted its holdings in Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after purchasing an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Pfizer during the 1st quarter worth about $311,238,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $27.55 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The stock has a market capitalization of $156.00 billion, a PE ratio of 76.53, a P/E/G ratio of 1.24 and a beta of 0.61. The firm has a 50 day moving average of $27.43 and a two-hundred day moving average of $29.29.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.14 EPS. On average, research analysts predict that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PFE shares. Truist Financial lowered their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. UBS Group decreased their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $36.88.

Check Out Our Latest Research Report on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.